Cargando…
Antibody light chain variable domains and their biophysically improved versions for human immunotherapy
We set out to gain deeper insight into the potential of antibody light chain variable domains (V(L)s) as immunotherapeutics. To this end, we generated a naïve human V(L) phage display library and, by using a method previously shown to select for non-aggregating antibody heavy chain variable domains...
Autores principales: | Kim, Dae Young, To, Rebecca, Kandalaft, Hiba, Ding, Wen, van Faassen, Henk, Luo, Yan, Schrag, Joseph D, St-Amant, Nadereh, Hefford, Mary, Hirama, Tomoko, Kelly, John F, MacKenzie, Roger, Tanha, Jamshid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929445/ https://www.ncbi.nlm.nih.gov/pubmed/24423624 http://dx.doi.org/10.4161/mabs.26844 |
Ejemplares similares
-
Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease
por: Kandalaft, Hiba, et al.
Publicado: (2015) -
Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability
por: Hussack, Greg, et al.
Publicado: (2011) -
Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human V(H)/V(L) Single-Domain Antibodies from In Vitro Display Libraries
por: Henry, Kevin A., et al.
Publicado: (2017) -
Neutralization of Clostridium difficile toxin B with V(H)H-Fc fusions targeting the delivery and CROPs domains
por: Hussack, Greg, et al.
Publicado: (2018) -
Structure-guided design of a potent Clostridioides difficile toxin A inhibitor
por: Hussack, Greg, et al.
Publicado: (2023)